Post-Operative Cataract Surgery Inflammation - Pipeline Insight, 2024

This Post-Operative Cataract Surgery Inflammation - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Post-Operative Cataract Surgery Inflammation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Post-Operative Cataract Surgery Inflammation Understanding

Post-Operative Cataract Surgery Inflammation: Overview

Cataract surgery is the most common surgical procedure in ophthalmology practice, and the number of surgeries is assumed to increase in the future because cataracts are an age-related condition and life expectancy is increasing in most countries. The high number of surgeries performed is also due to good outcomes for the surgical treatment of cataracts. Inflammation after cataract surgery, which can be persistent, remains an undesirable consequence despite many advances in surgical techniques. Although corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) have traditionally been used to treat inflammation, prophylactically as well as post-operatively, there are no established guidelines for the treatment of inflammation induced by cataract surgery. The long-term use of corticosteroids has raised safety concerns, especially with regard to elevated intraocular pressure (IOP). This limitation of traditional corticosteroids led to the development of C-20 ester corticosteroids through retrometabolic drug design.

Post-Operative Cataract Surgery Inflammation - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Post-Operative Cataract Surgery Inflammation pipeline landscape is provided which includes the disease overview and Post-Operative Cataract Surgery Inflammation treatment guidelines. The assessment part of the report embraces, in depth Post-Operative Cataract Surgery Inflammation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Post-Operative Cataract Surgery Inflammation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Post-Operative Cataract Surgery Inflammation R&D. The therapies under development are focused on novel approaches to treat/improve Post-Operative Cataract Surgery Inflammation.

This segment of the Post-Operative Cataract Surgery Inflammation report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Post-Operative Cataract Surgery Inflammation Drugs
APP13007: Formosa Pharmaceuticals APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), a novel formulation of the potent corticosteroid, clobetasol propionate, for the treatment of inflammation and pain after cataract surgery. APP13007 was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration.

Post-Operative Cataract Surgery Inflammation: Therapeutic Assessment

This segment of the report provides insights about the Post-Operative Cataract Surgery Inflammation drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Post-Operative Cataract Surgery Inflammation

There are approx. 5+ key companies which are developing the therapies for Post-Operative Cataract Surgery Inflammation. The companies which have their Post-Operative Cataract Surgery Inflammation drug candidates in the most advanced stage, i.e. Phase II include Formosa Pharmaceuticals.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Post-Operative Cataract Surgery Inflammation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Post-Operative Cataract Surgery Inflammation: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Post-Operative Cataract Surgery Inflammation therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Post-Operative Cataract Surgery Inflammation drugs.

Post-Operative Cataract Surgery Inflammation Report Insights

• Post-Operative Cataract Surgery Inflammation Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Post-Operative Cataract Surgery Inflammation Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Post-Operative Cataract Surgery Inflammation drugs?
• How many Post-Operative Cataract Surgery Inflammation drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Post-Operative Cataract Surgery Inflammation?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Post-Operative Cataract Surgery Inflammation therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Post-Operative Cataract Surgery Inflammation and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Oculis
• Formosa Pharmaceuticals
• VisusNano
• Surface Ophthalmics
• Mati Therapeutics

Key Products

• OCS-01
• APP13007
• SURF-201
• Nepafenac PPDS

This product will be delivered within 2 business days.